uric acid and Ache
uric acid has been researched along with Ache in 138 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although previous findings indicated that allopurinol could present intrinsic analgesic effects in both animals and humans, this study showed no benefit of the use of oral allopurinol as an adjuvant strategy during 30 days in women displaying fibromyalgia." | 9.51 | Allopurinol for fibromyalgia pain in adults: A randomized controlled trial. ( Andrade, CF; Botelho, LM; de Oliveira, ED; Dos Santos, LMM; Fagundes, AC; Ferrari, SG; Lara, DR; Schmidt, AP; Schmidt, SRG; Souza, DO, 2022) |
| "A dosage of 300 mg/d of allopurinol was not effective in reducing pain or improving activities of daily living in chronic pancreatitis." | 9.08 | Does allopurinol reduce pain of chronic pancreatitis? ( Banks, PA; Ferrante, M; Hughes, M; Noordhoek, EC; Ramagopal, V; Slivka, A, 1997) |
| "In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis." | 9.04 | Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial. ( Donovan, JF; Hearron, MS; Levi, L; Moxley, TE; Royer, GL, 1975) |
| "Eucalyptol alleviates MSU-induced pain and inflammation via mechanisms possibly involving anti-oxidative effect." | 7.96 | Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. ( Li, X; Li, Y; Liu, B; Tai, Y; Wang, C; Wang, P; Yin, C; Zheng, X, 2020) |
| "Retigabine and flupirtine showed antinociceptive effects for MSU-induced gout pain at different times during pain development." | 7.96 | Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020) |
| "Procyanidins significantly attenuated gout pain and suppressed ankle swelling." | 7.85 | Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression. ( Fan, YX; Gui, X; Han, Y; Hu, L; Jiang, CY; Liu, BQ; Liu, HJ; Liu, WT; Pan, XX; Tang, YL, 2017) |
| "The purpose of this work was to evaluate the antinociceptive efficacy of an optimal morphine and metamizol combination on different levels of nociception (levels I, II, and III) using the "Pain-induced functional impairment model in the rat"." | 7.74 | The antinociceptive efficacy of morphine, metamizol, or their combination in an experimental rat model with different levels of inflammatory pain. ( Cortés-Arroyo, AR; Domínguez-Ramírez, AM; Godínez-Chaparro, B; Guevara-López, U; Huerta-Cruz, JC; López-Muñoz, FJ, 2008) |
| "The potential antinociceptive effects of the S(+)- and R(-)-enantiomers of flurbiprofen (SFB and RFB, respectively) were investigated when given intravenously to rats using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain." | 7.70 | Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain. ( Cabré, F; Díaz, MI; Domínguez, AM; García, ML; Hernández, GP; López-Muñoz, FJ; Mauleón, D; Ventura, R, 2000) |
| "We investigated the antinociceptive properties of dexketoprofen trometamol [S(+)-ketoprofen tromethamine salt; SKP], a new analgesic, antiinflammatory drug, using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain." | 7.70 | Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. ( Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998) |
| "The analgesic activities of paracetamol (100, 178, 316 and 562 mg kg-1), caffeine (10, 18, 32 and 56 mg kg-1) and combinations of these doses were tested on a pain-induced functional impairment model in the rat." | 7.68 | Characterization of the analgesic effect of paracetamol and caffeine combinations in the pain-induced functional impairment model in the rat. ( Castañeda-Hernández, G; Flores-Murrieta, FJ; Granados-Soto, V; López-Muñoz, FJ; Salazar, LA; Villarreal, JE, 1993) |
| "Suprofen, a nonsteroidal anti-inflammatory drug, has been associated with the onset of acute flank pain, hematuria, and transient renal dysfunction after the ingestion of one or two doses, particularly in young males." | 7.67 | Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain. ( Abraham, PA; Halstenson, CE; Keane, WF; Matzke, GR; Opsahl, JA, 1988) |
| "Carprofen was also somewhat effective in attenuating the severity of urate-induced synovitis but to a lesser degree than the medium dose of deracoxib." | 6.70 | Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. ( Buonomo, FC; Millis, DL; Moyers, T; Weigel, JP, 2002) |
| " Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months." | 6.64 | Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin. ( Balme, HW; Berry, H; Hart, FD; Huskisson, EC; Scott, J; Wojtulewski, JA, 1974) |
| "Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities." | 5.91 | Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023) |
| "Although previous findings indicated that allopurinol could present intrinsic analgesic effects in both animals and humans, this study showed no benefit of the use of oral allopurinol as an adjuvant strategy during 30 days in women displaying fibromyalgia." | 5.51 | Allopurinol for fibromyalgia pain in adults: A randomized controlled trial. ( Andrade, CF; Botelho, LM; de Oliveira, ED; Dos Santos, LMM; Fagundes, AC; Ferrari, SG; Lara, DR; Schmidt, AP; Schmidt, SRG; Souza, DO, 2022) |
| " The assessed outcomes were total effective rate, uric acid level, pain score, and inflammatory factor levels such as erythrocyte sedimentation rate and C-reactive protein." | 5.41 | Herbal medicine for external use in acute gouty arthritis: A PRISMA-compliant systematic review and meta-analysis. ( Choi, SH; Hwang, J; Song, HS, 2023) |
| "The optimum doses of carprofen, flunixin, ketoprofen and sodium salicylate for the treatment of inflammatory pain were determined in domestic fowl using the microcrystalline sodium urate model of articular pain." | 5.11 | Effects of non-steroidal anti-inflammatory drugs on pain-related behaviour in a model of articular pain in the domestic fowl. ( Gentle, MJ; Hocking, PM; Robertson, GW, 2005) |
| "A dosage of 300 mg/d of allopurinol was not effective in reducing pain or improving activities of daily living in chronic pancreatitis." | 5.08 | Does allopurinol reduce pain of chronic pancreatitis? ( Banks, PA; Ferrante, M; Hughes, M; Noordhoek, EC; Ramagopal, V; Slivka, A, 1997) |
| "In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis." | 5.04 | Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial. ( Donovan, JF; Hearron, MS; Levi, L; Moxley, TE; Royer, GL, 1975) |
| "Along with uric acid, which is the primary driving factor of gout, downstream inflammatory mediators have been shown to be involved in the pathogenesis of gouty arthritis flares." | 4.12 | Plasma adsorption in refractory chronic gouty arthritis flare: A case report. ( Cui, TJ; Lei, Y; Tang, C; Wang, XH; Zhang, XM; Zheng, ZH, 2022) |
| "Eucalyptol alleviates MSU-induced pain and inflammation via mechanisms possibly involving anti-oxidative effect." | 3.96 | Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. ( Li, X; Li, Y; Liu, B; Tai, Y; Wang, C; Wang, P; Yin, C; Zheng, X, 2020) |
| "Retigabine and flupirtine showed antinociceptive effects for MSU-induced gout pain at different times during pain development." | 3.96 | Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020) |
| "Procyanidins significantly attenuated gout pain and suppressed ankle swelling." | 3.85 | Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression. ( Fan, YX; Gui, X; Han, Y; Hu, L; Jiang, CY; Liu, BQ; Liu, HJ; Liu, WT; Pan, XX; Tang, YL, 2017) |
| " Further, an acetic acid-induced writhing test and tail immersion test were employed to screen for analgesic effects, yeast-induced pyrexia was used to test for antipyretic effects, and gastric ulceration was used to evaluate ulcerogenic effects." | 3.79 | Dietary component p-coumaric acid suppresses monosodium urate crystal-induced inflammation in rats. ( Pragasam, SJ; Rasool, M, 2013) |
| "Diazepam-reduced experimental anxiety was paralleled by antinociceptive effects." | 3.76 | Parallel anxiolytic-like and antinociceptive actions of diazepam in the anterior basolateral amygdala and dorsal periaqueductal gray. ( Fernández-Guasti, A; Jiménez-Velázquez, G; López-Muñoz, FJ, 2010) |
| "The aim of this study is to evaluate connection of plasma level of beta2-microglobulin, C-reactive protein and uric acid as well as sonographic parameters like thickness of synovial membrane, thickness of femoral condylar cartilage and presence of joint effusion and Baker's cysts with bilateral knee pain in dialyzed patients, comparing them with parameters in asymptomatic dialyzed patients." | 3.74 | Laboratory and sonographic findings in dialyzed patients with bilateral chronic knee pain versus dialyzed asymptomatic patients. ( Barisić, I; Bekavac, J; Janković, S; Ljutić, D; Vlak, T, 2007) |
| "The purpose of this work was to evaluate the antinociceptive efficacy of an optimal morphine and metamizol combination on different levels of nociception (levels I, II, and III) using the "Pain-induced functional impairment model in the rat"." | 3.74 | The antinociceptive efficacy of morphine, metamizol, or their combination in an experimental rat model with different levels of inflammatory pain. ( Cortés-Arroyo, AR; Domínguez-Ramírez, AM; Godínez-Chaparro, B; Guevara-López, U; Huerta-Cruz, JC; López-Muñoz, FJ, 2008) |
| " The role of factors with anxiogenic properties produced during inflammation, which may modify diazepam and buspirone effects, is discussed." | 3.73 | Influence of inflammatory nociception on the anxiolytic-like effect of diazepam and buspirone in rats. ( Fernández-Guasti, A; López-Muñoz, FJ; Martínez-Mota, L; Reyes, R, 2005) |
| "The role of nitric oxide (NO) in the antinociceptive effect of indomethacin was assessed in the pain-induced functional impairment model in the rat (PIFIR model), a model of inflammatory and chronic pain similar to that observed in clinical gout." | 3.72 | Peripheral involvement of the nitric oxide-cGMP pathway in the indomethacin-induced antinociception in rat. ( Déciga-Campos, M; Díaz-Reval, MI; González-Trujano, ME; López-Muñoz, FJ; Ventura-Martínez, R, 2004) |
| "We investigated the antinociceptive properties of dexketoprofen trometamol [S(+)-ketoprofen tromethamine salt; SKP], a new analgesic, antiinflammatory drug, using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain." | 3.70 | Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. ( Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998) |
| "The potential antinociceptive effects of the S(+)- and R(-)-enantiomers of flurbiprofen (SFB and RFB, respectively) were investigated when given intravenously to rats using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain." | 3.70 | Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain. ( Cabré, F; Díaz, MI; Domínguez, AM; García, ML; Hernández, GP; López-Muñoz, FJ; Mauleón, D; Ventura, R, 2000) |
| "The presence of nausea and vomiting, epigastric pain, or both in association with admission laboratory values that are in excess of the cutoffs for lactate dehydrogenase, aspartate aminotransferase, and uric acid concentrations or for all 6 tests is predictive of high risk of morbidity for the patient with severe preeclampsia." | 3.70 | Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. ( Blake, PG; Magann, EF; Martin, JN; May, WL; Rinehart, BK; Terrone, DA, 1999) |
| "The analgesic activities of paracetamol (100, 178, 316 and 562 mg kg-1), caffeine (10, 18, 32 and 56 mg kg-1) and combinations of these doses were tested on a pain-induced functional impairment model in the rat." | 3.68 | Characterization of the analgesic effect of paracetamol and caffeine combinations in the pain-induced functional impairment model in the rat. ( Castañeda-Hernández, G; Flores-Murrieta, FJ; Granados-Soto, V; López-Muñoz, FJ; Salazar, LA; Villarreal, JE, 1993) |
| "In previous studies we reported that the rat spinal cord contains relatively high levels of uric acid and that the levels in a rat model of bilateral chronic pain, experimental adjuvant arthritis." | 3.67 | Effect of deafferentation on the levels of uric acid in the spinal cord of the rat. ( Basbaum, AI; Godefroy, F; Weil-Fugazza, J, 1989) |
| "Suprofen, a nonsteroidal anti-inflammatory drug, has been associated with the onset of acute flank pain, hematuria, and transient renal dysfunction after the ingestion of one or two doses, particularly in young males." | 3.67 | Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain. ( Abraham, PA; Halstenson, CE; Keane, WF; Matzke, GR; Opsahl, JA, 1988) |
| " Surface electromyograms were used to evaluate the muscle spasm theory; the possibility of actual muscle cell damage was monitored by the presence of myoglobinuria, while the ratio of hydroxyproline/creatinine (OHP/Cr) in 24 hr urine collection was used as a marker for connective tissue involvement." | 3.65 | Factors in delayed muscle soreness. ( Abraham, WM, 1977) |
| "Gout is triggered by high urate levels and causes inflammation, pain, and an impaired quality of life." | 3.30 | Immersion in Water Between 20-30 ( Chou, KR; Karwur, FF; Kurniasari, MD; Miao, NF; Rayanti, RE; Shen, CJ; Shih, YW; Tsai, HT; Yuliana, S, 2023) |
| "The primary outcomes will be joint pain measured by VAS score, and joint swelling measured using width and thickness of affected joints and VAS score." | 3.11 | Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial. ( Dong, X; Huang, JY; Li, XP; Liu, JP; Liu, Y; Shang, YX; Wang, XC; Wei, SF; Xie, ZM, 2022) |
| " To investigate the potency of MSU crystals as a cancer vaccine carrier in vivo, this preclinical study examined whether intradermal injection of MSU crystals was safe for healthy adults." | 2.76 | Safety of intradermal injection of monosodium urate crystals as a vaccine carrier in volunteers. ( Inai, K; Sakamaki, I; Tsutani, H, 2011) |
| " The treatment group was treated by jiawei simiaosan and combined with the external application of Sihuangshuimi." | 2.73 | [A clinical research of Jiawei simiaosan oral administration combined with the external application of Sihuangshuimi in the treatment of acute gouty arthritis]. ( Chen, SQ; Chen, ZX; Sun, BG; Ye, XY; Yin, LR; Zhou, HM, 2007) |
| "To study the therapeutic effect of treatment of acute gouty arthritis (AGA) respectively by electroacupuncture (EA) with different frequency and oral intake of Western medicine." | 2.72 | Comparative study on treatment of acute gouty arthritis by electroacupuncture with different frequency. ( Zhang, HX; Zhang, TF; Zou, R, 2006) |
| "Carprofen was also somewhat effective in attenuating the severity of urate-induced synovitis but to a lesser degree than the medium dose of deracoxib." | 2.70 | Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. ( Buonomo, FC; Millis, DL; Moyers, T; Weigel, JP, 2002) |
| " It is concluded that the arthralgia was often self-limiting, that aspirin had a small beneficial effect, that allopurinol, in the dosage studied, may have had a slightly deleterious effect, but that it would be worth studying larger dosages of allopurinol because the dosage studied did not affect the serum uric acid concentration." | 2.65 | Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. ( Allan, WG; Fox, W; Girling, DJ; Horsfall, PA; Nunn, AJ; Plummer, J, 1979) |
| " Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months." | 2.64 | Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin. ( Balme, HW; Berry, H; Hart, FD; Huskisson, EC; Scott, J; Wojtulewski, JA, 1974) |
| "The pharmacological treatment of pain in CIA is strictly associated with the treatment of acute phases and flares of the disease, during which crystals trigger the inflammatory response." | 2.52 | Molecular mechanisms of pain in crystal-induced arthritis. ( Frallonardo, P; Galozzi, P; Lorenzin, M; Oliviero, F; Ortolan, A; Punzi, L; Ramonda, R; Scanu, A, 2015) |
| "Gout is the most common cause of inflammatory arthritis among men and postmenopausal women." | 2.46 | Gout: epitome of painful arthritis. ( VanItallie, TB, 2010) |
| "We describe here a new type of acute renal failure with severe loin pain which develops after anaerobic exercise (ALPE), for example, 200-meter track racing." | 2.41 | Acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise in patients with or without renal hypouricemia. ( Ishikawa, I, 2002) |
| "Gouty arthritis is characterized by painful inflammation due to the deposition of monosodium urate crystals in joint tissues." | 1.91 | Articular mobilization promotes improvement in functional and inflammatory parameters in a gouty arthritis model. ( Bertolini, GRF; Costa, RM; Hoss, IM; Leal, TSDS; Pradal, LA; Ribeiro, LFC, 2023) |
| "Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities." | 1.91 | Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023) |
| "Mechanical hyperalgesia was conducted using the electronic von Frey." | 1.72 | Regulation of TRPV1 channel in monosodium urate-induced gouty arthritis in mice. ( Li, G; Xu, X; Yuan, Z; Zhang, G; Zhang, S, 2022) |
| "RvD1 inhibited MSU-induced mechanical hyperalgesia in a dose- and time-dependent manner by reducing leukocyte recruitment and IL-1β production in the knee joint." | 1.72 | RvD1 disrupts nociceptor neuron and macrophage activation and neuroimmune communication, reducing pain and inflammation in gouty arthritis in mice. ( Amaral, FA; Andrade, KC; Artero, NA; Badaro-Garcia, S; Bertozzi, MM; Borghi, SM; Casagrande, R; Fattori, V; Ferraz, CR; Manchope, MF; Rasquel-Oliveira, F; Rogers, MS; Saraiva-Santos, T; Staurengo-Ferrari, L; Teixeira, MM; Verri, WA; Zaninelli, TH, 2022) |
| "Pain was determined using the electronic von Frey and static weight bearing." | 1.56 | IL-33 enhances macrophage release of IL-1β and promotes pain and inflammation in gouty arthritis. ( Alves-Filho, JC; Amaral, FA; Casagrande, R; Cunha, FQ; Cunha, TM; Fattori, V; Louzada-Junior, P; Oliveira, RD; Staurengo-Ferrari, L; Teixeira, MM; Verri, WA; Zaninelli, TH, 2020) |
| "The swelling degree reached its maximum at 10 h and the minimum pain threshold was maintained between 8 and 48 h after MSU treatment in mice." | 1.56 | Characteristics of voltage-gated potassium currents in monosodium urate induced gouty arthritis in mice. ( Hong, J; Qiu, J; Wang, X; Zhang, G, 2020) |
| "Gout is the most common inflammatory arthritis in adults in the Western world." | 1.43 | Gout: will the "King of Diseases" be the first rheumatic disease to be cured? ( Singh, JA, 2016) |
| "Pain was measured before and during the TDP using the Premature Infant Pain Profile (PIPP)." | 1.38 | Procedural pain and oxidative stress in premature neonates. ( Angeles, DM; Angeles, KR; Ashwal, S; Asmerom, Y; Bahjri, K; Boskovic, DS; Deming, D; Fayard, E; Hougland, K; Phillips, R; Plank, MS; Slater, L, 2012) |
| "Gout is a common rheumatologic condition of recurrent polyarticular involvement." | 1.37 | Unknown: Multiple painful nodules - what is the diagnosis? Chronic tophaceous gout. ( Avhad, G; Dandale, A; Dhurat, R; Ghate, S, 2011) |
| "Urolithiasis is one of the commonest problems in pediatric nephrology." | 1.36 | Clinical manifestations and etiology of renal stones in children less than 14 years age. ( Heidari, A; Sepahi, MA; Shajari, A, 2010) |
| "Allopurinol is an old and extensively used compound and seems to be well tolerated with no obvious central nervous system toxic effects at high doses." | 1.35 | Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. ( Antunes, C; Böhmer, AE; Elisabetsky, E; Lara, DR; Porciúncula, LO; Schallenberger, C; Schmidt, AP; Souza, DO, 2009) |
| "Flank pain was the most common manifestation." | 1.31 | Urolithiasis in childhood. ( Gündüz, Z; Kabaklioğlu, M; Küçükaydin, M; Okur, H; Ozokutan, BH; Turan, C, 2000) |
| "Bone pain (82%), headache (70%), fatigue (20%), and nausea (10%) were reported." | 1.29 | Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. ( Anderlini, P; Champlin, R; Chan, KW; Körbling, M; Lichtiger, B; Miller, P; Norfleet, F; Przepiorka, D; Seong, D; Sundberg, J, 1996) |
| "It is shown that in osteoarthrosis the clinical characteristics vary from one joint group to another." | 1.26 | Heberden Oration 1981: epidemiology and the arthritides. ( Acheson, RM, 1982) |
| "A review of 869 cases of multiple myeloma seen at the Mayo Clinic from 1960 through 1971 revealed that 98% of patients were 40 years of age or older and that 61% of them were males." | 1.25 | Multiple myeloma: review of 869 cases. ( Kyle, RA, 1975) |
Research
Studies (138)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 40 (28.99) | 18.7374 |
| 1990's | 18 (13.04) | 18.2507 |
| 2000's | 26 (18.84) | 29.6817 |
| 2010's | 33 (23.91) | 24.3611 |
| 2020's | 21 (15.22) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Goo, B | 1 |
| Lee, J | 1 |
| Park, C | 1 |
| Yune, T | 1 |
| Park, Y | 1 |
| Hannarici, Z | 1 |
| Yılmaz, A | 1 |
| Buyukbayram, ME | 1 |
| Turhan, A | 1 |
| Tekin, SB | 1 |
| Bilici, M | 1 |
| Keenan, RT | 1 |
| Yeo, AE | 1 |
| Lipsky, PE | 1 |
| Xu, X | 1 |
| Yuan, Z | 1 |
| Zhang, S | 1 |
| Li, G | 1 |
| Zhang, G | 2 |
| Shang, YX | 1 |
| Dong, X | 1 |
| Xie, ZM | 1 |
| Li, XP | 1 |
| Wang, XC | 1 |
| Huang, JY | 1 |
| Wei, SF | 1 |
| Liu, Y | 2 |
| Liu, JP | 1 |
| Zaninelli, TH | 3 |
| Fattori, V | 3 |
| Saraiva-Santos, T | 1 |
| Badaro-Garcia, S | 2 |
| Staurengo-Ferrari, L | 3 |
| Andrade, KC | 2 |
| Artero, NA | 1 |
| Ferraz, CR | 1 |
| Bertozzi, MM | 1 |
| Rasquel-Oliveira, F | 1 |
| Manchope, MF | 1 |
| Amaral, FA | 2 |
| Teixeira, MM | 2 |
| Borghi, SM | 2 |
| Rogers, MS | 1 |
| Casagrande, R | 3 |
| Verri, WA | 3 |
| Topless, R | 1 |
| Noorbaloochi, S | 1 |
| Merriman, TR | 1 |
| Singh, JA | 3 |
| Kurniasari, MD | 1 |
| Karwur, FF | 1 |
| Rayanti, RE | 1 |
| Shih, YW | 1 |
| Yuliana, S | 1 |
| Miao, NF | 1 |
| Chou, KR | 1 |
| Shen, CJ | 1 |
| Tsai, HT | 1 |
| Lei, Y | 2 |
| Cui, TJ | 2 |
| Wang, XH | 2 |
| Zhang, XM | 2 |
| Tang, C | 2 |
| Zheng, ZH | 2 |
| Cao, Y | 1 |
| Hu, Y | 1 |
| Jin, XF | 1 |
| Zou, JM | 1 |
| Lee, YH | 1 |
| Song, GG | 1 |
| Choi, SH | 1 |
| Song, HS | 1 |
| Hwang, J | 1 |
| Hoss, IM | 1 |
| Pradal, LA | 1 |
| Leal, TSDS | 1 |
| Bertolini, GRF | 1 |
| Costa, RM | 1 |
| Ribeiro, LFC | 1 |
| Yin, C | 2 |
| Liu, B | 4 |
| Wang, P | 2 |
| Li, X | 2 |
| Li, Y | 2 |
| Zheng, X | 2 |
| Tai, Y | 2 |
| Wang, C | 1 |
| Zhang, F | 1 |
| Liu, S | 1 |
| Jin, L | 1 |
| Tang, L | 1 |
| Zhao, X | 1 |
| Yang, T | 1 |
| Wang, Y | 2 |
| Huo, B | 1 |
| Liu, R | 1 |
| Li, H | 1 |
| Hong, J | 1 |
| Qiu, J | 1 |
| Wang, X | 1 |
| Oliveira, RD | 1 |
| Louzada-Junior, P | 1 |
| Cunha, TM | 2 |
| Alves-Filho, JC | 2 |
| Cunha, FQ | 2 |
| Wang, J | 1 |
| Chen, R | 1 |
| Shou, Q | 1 |
| Shao, X | 1 |
| Liang, Y | 1 |
| Zhou, H | 1 |
| Mi, W | 1 |
| Fang, J | 1 |
| López-Reyes, A | 1 |
| Medina-Luna, D | 1 |
| Santamaría-Olmedo, M | 1 |
| Martínez-Flores, K | 1 |
| Zamudio-Cuevas, Y | 1 |
| Fernández-Torres, J | 1 |
| Martínez-Nava, GA | 1 |
| Olivos-Meza, A | 1 |
| Camacho-Rea, C | 1 |
| Fernández-Moreno, M | 1 |
| Blanco, FJ | 1 |
| Pineda, C | 1 |
| Feng, J | 1 |
| Set Byeol, K | 1 |
| Hee Jung, L | 1 |
| Su Min, S | 1 |
| Soon Sung, L | 1 |
| Hong Won, S | 1 |
| Fagundes, AC | 1 |
| de Oliveira, ED | 1 |
| Ferrari, SG | 1 |
| Dos Santos, LMM | 1 |
| Botelho, LM | 1 |
| Schmidt, SRG | 1 |
| Andrade, CF | 1 |
| Lara, DR | 2 |
| Souza, DO | 2 |
| Schmidt, AP | 2 |
| Liu, HJ | 1 |
| Pan, XX | 1 |
| Liu, BQ | 1 |
| Gui, X | 1 |
| Hu, L | 1 |
| Jiang, CY | 1 |
| Han, Y | 1 |
| Fan, YX | 1 |
| Tang, YL | 1 |
| Liu, WT | 1 |
| Zuo, J | 1 |
| He, H | 1 |
| Zuo, Z | 1 |
| Bou-Chacra, N | 1 |
| Löbenberg, R | 1 |
| Nakano, Y | 1 |
| Otsuka, F | 1 |
| Ruiz-Miyazawa, KW | 1 |
| Pinho-Ribeiro, FA | 1 |
| Clemente-Napimoga, JT | 1 |
| Fraceto, LF | 1 |
| Napimoga, MH | 1 |
| Alammari, YM | 1 |
| Gheta, D | 1 |
| Flood, RM | 1 |
| Boran, G | 1 |
| Kane, DJ | 1 |
| Mullan, RH | 1 |
| Nery, RA | 1 |
| Skare, TL | 1 |
| Pragasam, SJ | 1 |
| Rasool, M | 1 |
| Kodithuwakku, ND | 1 |
| Pan, M | 1 |
| Zhu, YL | 1 |
| Zhang, YY | 1 |
| Feng, YD | 1 |
| Fang, WR | 1 |
| Li, YM | 1 |
| Shi, L | 1 |
| Xu, L | 1 |
| Yang, Y | 1 |
| Song, H | 1 |
| Pan, H | 1 |
| Yin, L | 1 |
| Liu, LM | 1 |
| Cheng, SF | 1 |
| Shieh, PC | 1 |
| Lee, JC | 1 |
| Chen, JJ | 1 |
| Ho, CT | 1 |
| Kuo, SC | 1 |
| Kuo, DH | 1 |
| Huang, LJ | 1 |
| Way, TD | 1 |
| Silva, CR | 1 |
| Oliveira, SM | 1 |
| Hoffmeister, C | 2 |
| Funck, V | 1 |
| Guerra, GP | 1 |
| Trevisan, G | 2 |
| Tonello, R | 1 |
| Rossato, MF | 2 |
| Pesquero, JB | 1 |
| Bader, M | 1 |
| Oliveira, MS | 1 |
| McDougall, JJ | 1 |
| Ferreira, J | 2 |
| Moilanen, LJ | 1 |
| Hämäläinen, M | 1 |
| Lehtimäki, L | 1 |
| Nieminen, RM | 1 |
| Moilanen, E | 1 |
| Ramonda, R | 1 |
| Oliviero, F | 1 |
| Galozzi, P | 1 |
| Frallonardo, P | 1 |
| Lorenzin, M | 1 |
| Ortolan, A | 1 |
| Scanu, A | 1 |
| Punzi, L | 1 |
| Jaramillo-Morales, OA | 1 |
| Espinosa-Juárez, JV | 1 |
| Corona-Ramos, JN | 1 |
| López-Muñoz, FJ | 15 |
| Hassan, EA | 1 |
| Lambrechts, NE | 1 |
| Weng, HY | 1 |
| Snyder, PW | 1 |
| Breur, GJ | 1 |
| Godínez-Chaparro, B | 1 |
| Huerta-Cruz, JC | 1 |
| Guevara-López, U | 2 |
| Domínguez-Ramírez, AM | 1 |
| Cortés-Arroyo, AR | 1 |
| Kaneko, K | 1 |
| Taniguchi, N | 1 |
| Tanabe, Y | 1 |
| Nakano, T | 1 |
| Hasui, M | 1 |
| Nozu, K | 1 |
| Carroll, GL | 2 |
| Narbe, R | 2 |
| Peterson, K | 2 |
| Kerwin, SC | 2 |
| Taylor, L | 2 |
| DeBoer, M | 1 |
| Lundberg, GD | 1 |
| Böhmer, AE | 1 |
| Antunes, C | 1 |
| Schallenberger, C | 1 |
| Porciúncula, LO | 1 |
| Elisabetsky, E | 1 |
| Martínez, AL | 1 |
| González-Trujano, ME | 2 |
| Pellicer, F | 1 |
| Navarrete, A | 1 |
| Kimura, T | 1 |
| Iio, K | 1 |
| Imai, E | 1 |
| Rakugi, H | 1 |
| Isaka, Y | 1 |
| Hayashi, T | 1 |
| Sepahi, MA | 1 |
| Heidari, A | 1 |
| Shajari, A | 1 |
| Yang, X | 1 |
| Li, J | 1 |
| Ye, C | 1 |
| Song, X | 1 |
| Peláez-Ballestas, I | 1 |
| Hernández Cuevas, C | 1 |
| Burgos-Vargas, R | 1 |
| Hernández Roque, L | 1 |
| Terán, L | 1 |
| Espinoza, J | 1 |
| Esquivel-Valerio, JA | 1 |
| Goycochea-Robles, MV | 1 |
| Aceves, FJ | 1 |
| Bernard, AG | 1 |
| Ventura, L | 1 |
| Shumsky, C | 1 |
| Hernández Garduño, A | 1 |
| Vázquez-Mellado, J | 1 |
| Jiménez-Velázquez, G | 1 |
| Fernández-Guasti, A | 3 |
| Feldsein, JD | 1 |
| Wilke, VL | 1 |
| Evans, RB | 1 |
| Conzemius, MG | 1 |
| VanItallie, TB | 1 |
| Tausche, AK | 1 |
| Panzner, I | 1 |
| Aust, D | 1 |
| Wunderlich, C | 1 |
| Kuritzky, L | 1 |
| Panchal, R | 1 |
| Plank, MS | 2 |
| Boskovic, DS | 2 |
| Tagge, E | 1 |
| Chrisler, J | 1 |
| Slater, L | 2 |
| Angeles, KR | 2 |
| Angeles, DM | 2 |
| de Oliveira, SM | 1 |
| Gomez, MV | 1 |
| Hartsfield, SM | 1 |
| Sakamaki, I | 1 |
| Inai, K | 1 |
| Tsutani, H | 1 |
| Avhad, G | 1 |
| Dandale, A | 1 |
| Ghate, S | 1 |
| Dhurat, R | 1 |
| Asmerom, Y | 1 |
| Bahjri, K | 1 |
| Phillips, R | 1 |
| Deming, D | 1 |
| Ashwal, S | 1 |
| Hougland, K | 1 |
| Fayard, E | 1 |
| Strand, V | 1 |
| Khanna, D | 1 |
| Forsythe, A | 1 |
| Edwards, NL | 1 |
| Swięchowicz, S | 1 |
| Ostałowska, A | 1 |
| Kasperczyk, A | 1 |
| Nowak, D | 1 |
| Birkner, E | 1 |
| Kasperczyk, S | 1 |
| Ishikawa, I | 1 |
| Millis, DL | 1 |
| Weigel, JP | 1 |
| Moyers, T | 1 |
| Buonomo, FC | 1 |
| Ortega, LF | 1 |
| Herrera, JE | 2 |
| Salazar, LA | 4 |
| Tinajero, J | 2 |
| Déciga-Campos, M | 2 |
| Ventura-Martínez, R | 1 |
| Díaz-Reval, MI | 1 |
| Hocking, PM | 2 |
| Robertson, GW | 1 |
| Gentle, MJ | 4 |
| Reyes, R | 1 |
| Martínez-Mota, L | 1 |
| Zou, R | 1 |
| Zhang, HX | 1 |
| Zhang, TF | 1 |
| Sugimoto, T | 1 |
| Ide, R | 1 |
| Uzu, T | 1 |
| Kashiwagi, A | 1 |
| Barisić, I | 1 |
| Ljutić, D | 1 |
| Vlak, T | 1 |
| Bekavac, J | 1 |
| Janković, S | 1 |
| Regan, EA | 1 |
| Bowler, RP | 1 |
| Crapo, JD | 1 |
| Zhou, HM | 1 |
| Chen, SQ | 1 |
| Sun, BG | 1 |
| Yin, LR | 1 |
| Ye, XY | 1 |
| Chen, ZX | 1 |
| Ayala-Guerrero, F | 1 |
| Covarrubias-Gómez, A | 1 |
| Torres-González, R | 1 |
| Sarma, GR | 1 |
| Acharyulu, GS | 1 |
| Kannapiran, M | 1 |
| Murthy, PV | 1 |
| Gurumurthy, P | 1 |
| Tripathy, SP | 1 |
| Okuda, K | 1 |
| Nakahama, H | 2 |
| Miyakawa, H | 1 |
| Shima, K | 1 |
| Akerblom, HK | 1 |
| Koivukangas, T | 1 |
| Puukka, R | 1 |
| Mononen, M | 1 |
| Acheson, RM | 1 |
| Villalon, CM | 1 |
| Terron, JA | 2 |
| Granados-Soto, V | 2 |
| Castañeda-Hernández, G | 2 |
| Villarreal, JE | 1 |
| Flores-Murrieta, FJ | 2 |
| Hong, E | 1 |
| Andersson, HI | 1 |
| Ejlertsson, G | 1 |
| Leden, I | 1 |
| Rosenberg, C | 1 |
| Anderlini, P | 1 |
| Przepiorka, D | 1 |
| Seong, D | 1 |
| Miller, P | 1 |
| Sundberg, J | 1 |
| Lichtiger, B | 1 |
| Norfleet, F | 1 |
| Chan, KW | 1 |
| Champlin, R | 1 |
| Körbling, M | 1 |
| López Laur, JD | 1 |
| Chiapetta Menéndez, J | 1 |
| Shigenaga, T | 1 |
| Kato, M | 1 |
| Taguchi, K | 1 |
| Banks, PA | 1 |
| Hughes, M | 1 |
| Ferrante, M | 1 |
| Noordhoek, EC | 1 |
| Ramagopal, V | 1 |
| Slivka, A | 1 |
| Wylie, LM | 1 |
| Wisłowska, M | 1 |
| Sypuła, S | 1 |
| Kowalik, I | 1 |
| Reyes, G | 1 |
| Medina, R | 1 |
| Castillo, EF | 1 |
| Chaves, F | 1 |
| Valdes, B | 1 |
| Ventura, R | 2 |
| Díaz, I | 1 |
| Tost, D | 1 |
| Cabré, F | 2 |
| Mauleón, D | 2 |
| Martin, JN | 1 |
| May, WL | 1 |
| Magann, EF | 1 |
| Terrone, DA | 1 |
| Rinehart, BK | 1 |
| Blake, PG | 1 |
| Bernard, R | 1 |
| Dunn, LN | 1 |
| Ozokutan, BH | 1 |
| Küçükaydin, M | 1 |
| Gündüz, Z | 1 |
| Kabaklioğlu, M | 1 |
| Okur, H | 1 |
| Turan, C | 1 |
| Díaz, MI | 1 |
| Hernández, GP | 1 |
| Domínguez, AM | 1 |
| García, ML | 1 |
| Revelo, MP | 1 |
| Staffeld, C | 1 |
| Copley, JB | 1 |
| Fogo, AB | 1 |
| Nuño Mateo, FJ | 1 |
| Noval Menéndez, J | 1 |
| Mazorra Iraculis, M | 1 |
| Campoamor Serrano, M | 1 |
| Martínez, RV | 1 |
| Reval, M | 1 |
| Campos, MD | 1 |
| Domínguez, R | 1 |
| Watanabe, T | 1 |
| Zaloga, B | 1 |
| Hughes, JL | 1 |
| Hoda, RS | 1 |
| Bogner, G | 1 |
| Tilscher, H | 1 |
| Horsfall, PA | 1 |
| Plummer, J | 1 |
| Allan, WG | 1 |
| Girling, DJ | 1 |
| Nunn, AJ | 1 |
| Fox, W | 1 |
| King, RS | 1 |
| Wichman, BA | 1 |
| Heuckenkamp, PU | 1 |
| Abraham, WM | 1 |
| Schumann, D | 1 |
| Patterson, P | 1 |
| Moxley, TE | 1 |
| Royer, GL | 1 |
| Hearron, MS | 1 |
| Donovan, JF | 1 |
| Levi, L | 1 |
| Kyle, RA | 1 |
| Giudicelli, Y | 1 |
| Kaiser, JM | 1 |
| Pecquery, R | 1 |
| Remy, JM | 1 |
| Doury, P | 1 |
| Delahaye, RP | 1 |
| Leguay, G | 1 |
| Pattin, S | 1 |
| Metges, PJ | 1 |
| Montely, JM | 1 |
| Duret, JC | 1 |
| Salhi, A | 1 |
| Forseth, KO | 1 |
| Gran, JT | 1 |
| Horowitz, MD | 1 |
| Abbey, L | 1 |
| Sirota, DK | 1 |
| Spiera, H | 1 |
| Strom, BL | 1 |
| West, SL | 1 |
| Sim, E | 1 |
| Carson, JL | 1 |
| Weil-Fugazza, J | 1 |
| Godefroy, F | 1 |
| Basbaum, AI | 1 |
| Bradlow, A | 1 |
| Mowat, AG | 1 |
| Lacroix, C | 1 |
| Guyonnaud, C | 1 |
| Chaou, M | 1 |
| Duwoos, H | 1 |
| Lafont, O | 1 |
| Coderre, TJ | 1 |
| Wall, PD | 1 |
| Abraham, PA | 1 |
| Halstenson, CE | 1 |
| Opsahl, JA | 1 |
| Matzke, GR | 1 |
| Keane, WF | 1 |
| Dubinsky, B | 1 |
| Gebre-Mariam, S | 1 |
| Capetola, RJ | 1 |
| Rosenthale, ME | 1 |
| Inase, M | 1 |
| Otsuki, T | 1 |
| Fang, JZ | 1 |
| Bodem, H | 1 |
| Dormoy, O | 1 |
| Ajzenberg, D | 1 |
| Shiokawa, Y | 1 |
| Riseman, JE | 1 |
| Ostendorp, U | 1 |
| Sonntag, RW | 1 |
| Emmerson, BT | 1 |
| Pasotti, C | 1 |
| Barbieri, C | 1 |
| Buniva, G | 1 |
| Chierichetti, S | 2 |
| Pavelka, K | 2 |
| Susta, A | 1 |
| Vojtísek, O | 2 |
| Bremová, A | 2 |
| Kanková, D | 2 |
| Hándlová, D | 2 |
| Malecek, J | 1 |
| Huskisson, EC | 1 |
| Wojtulewski, JA | 1 |
| Berry, H | 1 |
| Scott, J | 1 |
| Hart, FD | 1 |
| Balme, HW | 1 |
| Borrie, P | 1 |
| Slack, J | 1 |
| Hutchison, JC | 1 |
| Ghiringhelli, F | 1 |
| Mazzi, C | 1 |
| Sutton, J | 1 |
| Coleman, MJ | 1 |
| Millar, AP | 1 |
| Lazarus, L | 1 |
| Russo, P | 1 |
| Fearnley, ME | 1 |
| Vadasz, I | 1 |
| Harkness, RA | 1 |
| Nicol, AD | 1 |
| van Arman, CG | 1 |
| Carlson, RP | 1 |
| Risley, EA | 1 |
| Thomas, RH | 1 |
| Nuss, GW | 1 |
Clinical Trials (7)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor[NCT01508702] | Phase 3 | 214 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)[NCT01391325] | Phase 4 | 1,735 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to[NCT01510158] | Phase 3 | 607 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceou[NCT01510769] | Phase 3 | 330 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response t[NCT01493531] | Phase 3 | 610 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Effectiveness and Safety of an Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health Among [NCT05170113] | 79 participants (Actual) | Interventional | 2021-11-02 | Completed | |||
| Effect of a Cold Water Immersion (CWI) on Pain in People With Gouty Arthritis: A Community Based Randomized Controlled Trial[NCT04587544] | 76 participants (Actual) | Interventional | 2019-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Number of Subjects With an sUA Level That is < 6.0 mg/dL
(NCT01508702)
Timeframe: 6 months
| Intervention | Number of Subjects (Number) |
|---|---|
| Lesinurad 400 mg | 32 |
| Placebo | 2 |
Incidence of Gout Flares
Proportion of subjects who experienced at least one gout flare requiring treatment during the study. (NCT01391325)
Timeframe: Every month for 6 months.
| Intervention | percentage of subjects (Number) |
|---|---|
| Allopurinol | 33.4 |
Proportion of Subjects With Serum Urate (sUA) Less Than 6.0 mg/dL
Proportion of subjects with serum urate (sUA) less than 6.0 mg/dL at Month 6 using Last Observation Carried Forward (LOCF) for subjects with missing values at Month 6. (NCT01391325)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Allopurinol | 43.4 |
Safety of Allopurinol
Proportion of subjects who experienced at least one Treatment Emergent Adverse Event (TEAE) during the study. (NCT01391325)
Timeframe: Every month for 6 months.
| Intervention | percentage of subjects (Number) |
|---|---|
| Allopurinol | 55.1 |
Mean Change From Baseline to Month 6 in SF-36 PCS+MCS
The SF-36 is a short-form health survey with 36 questions that yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical (PCS) and mental health (MCS) summary. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability. The component scores (PCS and MCS) are norm-based to a standard population with a mean of 50 and a standard deviation of 10. (NCT01391325)
Timeframe: Month 6
| Intervention | units on a scale (Mean) | |
|---|---|---|
| SF-36 Physical Component Summary | SF-36 Mental Health Component Summary | |
| Allopurinol | 3.88 | 0.71 |
Gout Flares
Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12 (NCT01510158)
Timeframe: 12 Months
| Intervention | Gout Flares (Mean) |
|---|---|
| Lesinurad 200 mg + Allopurinol | .60 |
| Lesinurad 400 mg + Allopurinol | .50 |
| Placebo + Allopurinol | .60 |
Proportion of Subjects With an sUA Level That is < 6.0 mg/dL
(NCT01510158)
Timeframe: 6 Months, analysis after all subjects complete 12 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.542 |
| Lesinurad 400 mg + Allopurinol | 0.592 |
| Placebo + Allopurinol | 0.279 |
Tophus
Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01510158)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0 |
| Lesinurad 400 mg + Allopurinol | 0.211 |
| Placebo + Allopurinol | 0.294 |
Complete or Partial Response of at Least One Tophus
Proportion of subjects with a best tophus response on at least 1 target tophus of complete (disappearance of at least 1 target tophus) or partial (≥ 50% decrease in the area of at least 1 target tophus) resolution by Month 12 (NCT01510769)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.566 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.587 |
| Placebo + Febuxostat 80 mg | 0.505 |
Complete Resolution of at Least One Target Tophus
Proportion of subjects who experience complete resolution of at least 1 target tophus by Month 12 (NCT01510769)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.255 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.303 |
| Placebo + Febuxostat 80 mg | 0.211 |
Quality of Life
Proportion of subjects with an improvement from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at least 0.25 at Month 12. The HAQ-DI assesses a patient's level of functional ability with items scores ranging from 0-3 with 0 being the least disability. (NCT01510769)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.442 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.333 |
| Placebo + Febuxostat 80 mg | 0.525 |
Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6
Proportion of subjects with an sUA level that is < 5.0 mg/dL by Month 6 (NCT01510769)
Timeframe: 6 months, analysis after all subjects complete 12 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.566 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.761 |
| Placebo + Febuxostat 80 mg | 0.468 |
Gout Flares
Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12. (NCT01493531)
Timeframe: 12 Months
| Intervention | Gout Flares (Mean) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.7 |
| Lesinurad 400 mg + Allopurinol | 0.8 |
| Placebo + Allopurinol | 0.9 |
Subjects With ≥ 1 Target Tophus at Baseline Who Experience Complete Resolution of at Least 1 Target Tophus by Month 12
Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01493531)
Timeframe: 12 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.314 |
| Lesinurad 400 mg + Allopurinol | 0.276 |
| Placebo + Allopurinol | 0.333 |
Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6.
Proportion of subjects with an sUA level that is < 6.0 mg/dL by Month 6. (NCT01493531)
Timeframe: 6 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.554 |
| Lesinurad 400 mg + Allopurinol | 0.665 |
| Placebo + Allopurinol | 0.233 |
Reviews
6 reviews available for uric acid and Ache
| Article | Year |
|---|---|
Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Pain; Uric Acid | 2023 |
Herbal medicine for external use in acute gouty arthritis: A PRISMA-compliant systematic review and meta-analysis.
Topics: Arthritis, Gouty; Herbal Medicine; Humans; Pain; Plant Extracts; Plants, Medicinal; Randomized Contr | 2023 |
Molecular mechanisms of pain in crystal-induced arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Calcium Pyrophosphate; Chondrocalc | 2015 |
Gout: epitome of painful arthritis.
Topics: Arthritis; Female; Gout; Humans; Hyperuricemia; Immunity, Innate; Male; Pain; Uric Acid | 2010 |
Acute renal failure with severe loin pain and patchy renal ischemia after anaerobic exercise in patients with or without renal hypouricemia.
Topics: Acute Kidney Injury; Adolescent; Adult; Exercise; Female; Humans; Ischemia; Kidney; Male; Pain; Tomo | 2002 |
The antialgesic drugs: human therapeutic correlates of their potency in laboratory animal models of hyperalgesia.
Topics: Acetylcholine; Administration, Oral; Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ar | 1987 |
Trials
18 trials available for uric acid and Ache
| Article | Year |
|---|---|
Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Arthralgia; Arthritis, Gouty; Double-Blind Method; Drugs, Chinese Herbal; Edema; Humans; Medi | 2022 |
Immersion in Water Between 20-30
Topics: Biomarkers; Gout; Humans; Immersion; Indonesia; Inflammasomes; Inflammation; Pain; Pain Management; | 2023 |
Allopurinol for fibromyalgia pain in adults: A randomized controlled trial.
Topics: Allopurinol; Animals; Double-Blind Method; Female; Fibromyalgia; Gout Suppressants; Humans; Pain; Pr | 2022 |
Dose range finding study for the efficacy of meloxicam administered prior to sodium urate-induced synovitis in cats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cats; Cross-Over Studies; Dose-Response Relationsh | 2011 |
Safety of intradermal injection of monosodium urate crystals as a vaccine carrier in volunteers.
Topics: Adjuvants, Immunologic; Adult; Crystallization; Female; Humans; Inflammation; Injections, Intraderma | 2011 |
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Gout; Gout Suppressants; Humans; Male; Midd | 2012 |
Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cyclooxygenase I | 2002 |
Effects of non-steroidal anti-inflammatory drugs on pain-related behaviour in a model of articular pain in the domestic fowl.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Chickens; Clonixin; Dose-Response Rela | 2005 |
Comparative study on treatment of acute gouty arthritis by electroacupuncture with different frequency.
Topics: Acupuncture Analgesia; Acute Disease; Adult; Aged; Arthritis, Gouty; Electroacupuncture; Female; Hum | 2006 |
[A clinical research of Jiawei simiaosan oral administration combined with the external application of Sihuangshuimi in the treatment of acute gouty arthritis].
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adult; Aged; Arthritis, Gouty; Body Te | 2007 |
Does allopurinol reduce pain of chronic pancreatitis?
Topics: Abdominal Pain; Activities of Daily Living; Adult; Allopurinol; Ankle; Blood Cell Count; Chronic Dis | 1997 |
Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration.
Topics: Adolescent; Adult; Aged; Allopurinol; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female | 1979 |
Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial.
Topics: Alanine Transaminase; Clinical Trials as Topic; Drug Evaluation; Humans; Ibuprofen; Osteoarthritis; | 1975 |
Clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in painful osteoarticular conditions.
Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Cell Count; Body Weight; Clinical Trials as Topic; Diur | 1972 |
Double-blind comparison of ibuprofen and phenylbutazone in the short-term treatment of rheumatoid arthritis.
Topics: Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Hematocrit; H | 1973 |
Double-blind comparison of alclofenac and phenylbutazone in the short-term treatment of rheumatoid arthritis.
Topics: Administration, Oral; Allyl Compounds; Anthropometry; Anti-Inflammatory Agents; Arthritis, Rheumatoi | 1973 |
Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin.
Topics: Acetaminophen; Arthritis, Rheumatoid; Aspirin; Body Temperature; Clinical Trials as Topic; Deafness; | 1974 |
The hypotensive action of ethacrynic acid.
Topics: Abdomen; Adult; Aged; Antihypertensive Agents; Black People; Blood Glucose; Blood Pressure Determina | 1968 |
Other Studies
114 other studies available for uric acid and Ache
| Article | Year |
|---|---|
Bee Venom Alleviated Edema and Pain in Monosodium Urate Crystals-Induced Gouty Arthritis in Rat by Inhibiting Inflammation.
Topics: Animals; Arthritis, Gouty; Bee Venoms; Disease Models, Animal; Edema; Humans; Inflammation; Male; Pa | 2021 |
Lipegfilgrastim may cause hyperleukocytosis.
Topics: Allopurinol; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Pain; P | 2022 |
Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Gout Suppressants; Humans; Pain; Polyethylene Glycols; Trea | 2022 |
Regulation of TRPV1 channel in monosodium urate-induced gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Calcium; Edema; Hyperalgesia; Mice; Pain; Transient Receptor Potential Ch | 2022 |
RvD1 disrupts nociceptor neuron and macrophage activation and neuroimmune communication, reducing pain and inflammation in gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Calcitonin Gene-Related Peptide; Docosahexaenoic Acids; Hyperalgesia; Inf | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress.
Topics: Animals; Arthritis, Gouty; Caspases; Cytokines; Dimethyl Fumarate; Gout; Inflammasomes; Lipopolysacc | 2023 |
Articular mobilization promotes improvement in functional and inflammatory parameters in a gouty arthritis model.
Topics: Animals; Arthritis, Gouty; Edema; Humans; Inflammation; Male; Pain; Rats; Rats, Wistar; Uric Acid | 2023 |
Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis.
Topics: Animals; Eucalyptol; Gout; Humans; Inflammation; Macrophages; Mice; Pain; Quality of Life; Uric Acid | 2020 |
Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.
Topics: Aminopyridines; Analgesics; Animals; Arthritis, Experimental; Arthritis, Gouty; Behavior, Animal; Ca | 2020 |
Characteristics of voltage-gated potassium currents in monosodium urate induced gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Ganglia, Spinal; Male; Mice, Inbred ICR; Neurons; Pain; Potassium Channel | 2020 |
IL-33 enhances macrophage release of IL-1β and promotes pain and inflammation in gouty arthritis.
Topics: Animals; Arthritis, Gouty; Female; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Inte | 2020 |
IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain.
Topics: Animals; Disease Models, Animal; Gout; Humans; Injections, Intra-Articular; Interleukin-1 Receptor-L | 2020 |
Soluble inflammatory mediators of synoviocytes stimulated by monosodium urate crystals induce the production of oxidative stress, pain, and inflammation mediators in chondrocytes : Secretome of synoviocytes induces chondrocyte damage.
Topics: Cells, Cultured; Chondrocytes; Humans; Hydrogen Peroxide; Inflammation Mediators; Oxidative Stress; | 2021 |
Effects of Salvia miltiorrhiza Bunge extract and its single components on monosodium urate-induced pain in vivo and lipopolysaccharide-induced inflammation in vitro.
Topics: Animals; Anti-Inflammatory Agents; Humans; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbr | 2021 |
Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression.
Topics: Animals; Ankle; Anti-Inflammatory Agents; Antioxidants; Colchicine; Cytokines; Gout; Grape Seed Extr | 2017 |
Erding Formula in hyperuricaemia treatment: unfolding traditional Chinese herbal compatibility using modern pharmaceutical approaches.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drugs, Chinese Herbal; Gene E | 2018 |
Auricle Pain Due to Tophi.
Topics: Arthritis, Gouty; Ear Auricle; Febuxostat; Gout Suppressants; Humans; Male; Middle Aged; Pain; Uric | 2019 |
15d-PGJ
Topics: Animals; Antioxidants; Arthritis, Experimental; Arthritis, Gouty; Inflammation; Male; Mice; Mice, In | 2018 |
Urate-lowering therapy (ULT) reduces non-episodic foot pain in patients who fail to meet ACR/EULAR 2015 gout classification criteria: an effect predicted by ultrasound and potential rationale for reclassification.
Topics: Case-Control Studies; Female; Foot Joints; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pain; | 2019 |
Serum uric acid and leg ulcers.
Topics: Biomarkers; Female; Humans; Leg Ulcer; Male; Middle Aged; Pain; Uric Acid; Wound Healing | 2019 |
Dietary component p-coumaric acid suppresses monosodium urate crystal-induced inflammation in rats.
Topics: Acetic Acid; Acid Phosphatase; Analgesics; Animals; Anti-Inflammatory Agents; Antipyretics; beta-Glu | 2013 |
Anti-inflammatory and antinociceptive effects of Chinese medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Capsules; Cells, Cultu | 2013 |
Suppressive effect of modified Simiaowan on experimental gouty arthritis: an in vivo and in vitro study.
Topics: Acetic Acid; Analgesics; Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis, Gouty; Cell Surv | 2013 |
The methanol extract of Euonymus laxiflorus, Rubia lanceolata and Gardenia jasminoides inhibits xanthine oxidase and reduce serum uric acid level in rats.
Topics: Animals; Disease Models, Animal; Euonymus; Formaldehyde; Gardenia; Gout; Hyperuricemia; Nociception; | 2014 |
The role of kinin B1 receptor and the effect of angiotensin I-converting enzyme inhibition on acute gout attacks in rodents.
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin B1 Receptor Antagonists | 2016 |
Urate crystal induced inflammation and joint pain are reduced in transient receptor potential ankyrin 1 deficient mice--potential role for transient receptor potential ankyrin 1 in gout.
Topics: Acetanilides; Animals; Cytokines; Disease Models, Animal; Gout; Inflammation; Mice; Mice, Knockout; | 2015 |
Nociceptive Alteration by High Sucrose Diet in Hypoestrogenic Wistar Rats.
Topics: Animals; Blood Glucose; Body Weight; Dietary Sucrose; Estrogens; Female; Glucose Tolerance Test; Ins | 2016 |
Effects of denervation of the hip joint on results of clinical observations and instrumented gait analysis in dogs with sodium urate crystal-induced synovitis.
Topics: Animals; Biomechanical Phenomena; Denervation; Dog Diseases; Dogs; Female; Gait; Hip Joint; Kinetics | 2016 |
Gout: will the "King of Diseases" be the first rheumatic disease to be cured?
Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Gout; Gout Suppressants; Humans; Inflammation; Pain; | 2016 |
The antinociceptive efficacy of morphine, metamizol, or their combination in an experimental rat model with different levels of inflammatory pain.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyrone; Dose-Respon | 2008 |
Oxidative imbalance in idiopathic renal hypouricemia.
Topics: Acute Kidney Injury; Anaerobiosis; Child; DNA Mutational Analysis; Exercise; Exercise Test; Female; | 2009 |
A pilot study: sodium urate synovitis as an acute model of inflammatory response using objective and subjective criteria to evaluate arthritic pain in cats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Area Under Curve; Cats; Female; Infl | 2008 |
Prednisolone and naproxen both work for pain relief in acute gout.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Clinical Trials as Topic; Double-Blind Method; Female; H | 2008 |
Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor | 2009 |
Antinociceptive effect and GC/MS analysis of Rosmarinus officinalis L. essential oil from its aerial parts.
Topics: Analgesics; Animals; Arthritis; Chromatography, Gas; Male; Mass Spectrometry; Naloxone; Narcotic Ant | 2009 |
Exercise-induced acute kidney injury with reversible posterior leukoencephalopathy syndrome.
Topics: Adolescent; Exercise; Humans; Kidney; Magnetic Resonance Imaging; Male; Pain; Posterior Leukoencepha | 2010 |
Clinical manifestations and etiology of renal stones in children less than 14 years age.
Topics: Adolescent; Child; Child, Preschool; Citric Acid; Cystinuria; Dysuria; Female; Fever; Genetic Predis | 2010 |
Theacrine, a purine alkaloid with anti-inflammatory and analgesic activities.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Camellia; Drug Evaluation, Preclinical; Female; Infla | 2010 |
Diagnosis of chronic gout: evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment.
Topics: Chronic Disease; Cohort Studies; Cross-Sectional Studies; Crystallization; European Union; Female; G | 2010 |
Parallel anxiolytic-like and antinociceptive actions of diazepam in the anterior basolateral amygdala and dorsal periaqueductal gray.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Area Under Curve; Behavior, Animal; Diazepam; Disea | 2010 |
Serum cortisol concentration and force plate analysis in the assessment of pain associated with sodium urate-induced acute synovitis in dogs.
Topics: Animals; Biomarkers; Dog Diseases; Dogs; Female; Gait; Hydrocortisone; Male; Pain; Reproducibility o | 2010 |
Disabling gout.
Topics: Arthrodesis; Biomarkers; Foot; Gout; Hallux Valgus; Humans; Magnetic Resonance Imaging; Male; Metata | 2010 |
Gout: nonsteroidal anti-inflammatory drugs and colchicine to prevent painful flares during early urate-lowering therapy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressants; Humans; Male; Pa | 2010 |
An animal model for measuring the effect of common NICU procedures on ATP metabolism.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Biomarkers; Catheterization, Central Venous; Ener | 2011 |
Role of TRPV1 in nociception and edema induced by monosodium urate crystals in rats.
Topics: Acrylamides; Anilides; Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Antioxidants; Bridged B | 2011 |
Unknown: Multiple painful nodules - what is the diagnosis? Chronic tophaceous gout.
Topics: Alcoholics; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Chronic Disease; Colch | 2011 |
Procedural pain and oxidative stress in premature neonates.
Topics: Humans; Infant, Newborn; Infant, Premature; Malondialdehyde; Oxidative Stress; Pain; Pain Measuremen | 2012 |
Evaluation of hyaluronic acid intra-articular injections in the treatment of primary and secondary osteoarthritis of the knee.
Topics: Aged; Albumins; Bilirubin; Ceruloplasmin; Female; Humans; Hyaluronic Acid; Hydrogen Peroxide; Inject | 2012 |
Evaluation of morphine analgesic activity in rats submitted to repetitive intra-articular injections of uric acid.
Topics: Analgesics, Opioid; Animals; Arthritis; Injections, Intra-Articular; Male; Morphine; Pain; Pain Meas | 2003 |
Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Cyclic GMP; Cyclooxygenase 2; Cyclooxyge | 2003 |
Peripheral involvement of the nitric oxide-cGMP pathway in the indomethacin-induced antinociception in rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Chronic Disease; Cyclic GMP; Disease Mod | 2004 |
Influence of inflammatory nociception on the anxiolytic-like effect of diazepam and buspirone in rats.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Aspirin; Behavior, Animal; Buspirone; D | 2005 |
Recurring exercise-induced acute renal failure with usual daily work.
Topics: Acute Kidney Injury; Humans; Ischemia; Kidney; Male; Middle Aged; Pain; Physical Exertion; Recurrenc | 2007 |
Laboratory and sonographic findings in dialyzed patients with bilateral chronic knee pain versus dialyzed asymptomatic patients.
Topics: beta 2-Microglobulin; Biomarkers; C-Reactive Protein; Humans; Kidney Failure, Chronic; Knee Joint; P | 2007 |
Joint fluid antioxidants are decreased in osteoarthritic joints compared to joints with macroscopically intact cartilage and subacute injury.
Topics: Age Factors; Cartilage, Articular; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix; Female; | 2008 |
Effect of acute gouty arthritis on sleep patterns: a preclinical study.
Topics: Animals; Arousal; Arthritis, Gouty; Behavior, Animal; Electrodes, Implanted; Electroencephalography; | 2009 |
Role of rifampicin in arthralgia induced by pyrazinamide.
Topics: Drug Therapy, Combination; Humans; Joint Diseases; Pain; Pyrazinamide; Rifampin; Tuberculosis, Pulmo | 1983 |
Arthritis induced in cat by sodium urate: a possible animal model for tonic pain.
Topics: Animals; Arthritis; Behavior, Animal; Cat Diseases; Cats; Disease Models, Animal; Gait; Injections, | 1984 |
The tolerance of increasing amounts of dietary xylitol in children.
Topics: Abdomen; Administration, Oral; Adolescent; Child; Cholesterol; Diarrhea; Female; Flatulence; Humans; | 1982 |
Heberden Oration 1981: epidemiology and the arthritides.
Topics: Adolescent; Adult; Age Factors; Aged; Body Weight; Connecticut; Female; Gout; Hand; Humans; Male; Ma | 1982 |
Analgesic interactions produced by combinations of dipyrone and morphine in the rat.
Topics: Analgesics; Animals; Dipyrone; Female; Hindlimb; Morphine; Pain; Pain Measurement; Rats; Rats, Wista | 1994 |
Characterization of the analgesic effect of paracetamol and caffeine combinations in the pain-induced functional impairment model in the rat.
Topics: Acetaminophen; Administration, Oral; Animals; Caffeine; Drug Combinations; Drug Synergism; Female; H | 1993 |
Comparison of the analgesic effects of ketorolac, morphine and aspirin in the rat.
Topics: Analgesics; Animals; Aspirin; Dose-Response Relationship, Drug; Female; Ketorolac; Morphine; Pain; P | 1993 |
Analgesic effects of multiple combinations of morphine and aspirin in the rat.
Topics: Analgesics; Animals; Aspirin; Drug Combinations; Female; Hindlimb; Injections, Intra-Articular; Morp | 1993 |
Characteristics of subjects with chronic pain, in relation to local and widespread pain report. A prospective study of symptoms, clinical findings and blood tests in subgroups of a geographically defined population.
Topics: Adult; Aged; Chronic Disease; Female; Humans; Male; Middle Aged; Musculoskeletal Diseases; Pain; Ran | 1996 |
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
Topics: Adolescent; Adult; Alkaline Phosphatase; Analgesics; Blood Transfusion, Autologous; Bone Marrow Tran | 1996 |
Pain-related behaviour following sodium urate arthritis is expressed in decerebrate chickens.
Topics: Animals; Arthritis; Behavior, Animal; Chickens; Decerebrate State; Disease Models, Animal; Pain; Tel | 1997 |
[Chronic orchialgia. A diagnostic and therapeutic hypothesis].
Topics: Adolescent; Adult; Humans; Male; Middle Aged; Pain; Pain Management; Testicular Diseases; Uric Acid | 1997 |
In vivo voltammetric studies of the effects of intrathecal morphine on noxious heat stimuli-induced serotonin release in the nucleus raphe magnus of anesthetized rats.
Topics: Animals; Electrochemistry; Hot Temperature; Hydroxyindoleacetic Acid; Injections, Spinal; Male; Morp | 1997 |
Feeding-induced tonic pain suppression in the chicken: reversal by naloxone.
Topics: Adaptation, Psychological; Analgesia; Animals; Arthritis, Gouty; Behavior, Animal; Chickens; Eating; | 1998 |
Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Glucose; Echocardiography; Electrocardiography; Electrocar | 1998 |
On the analgesic effect of sodium diclofenac in pain-induced functional impairment in the rat.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Diclofenac; Dose-Response Re | 1998 |
Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Biotransformation; Dise | 1998 |
Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Creatinine; Female; HELLP Syndrome; Humans; L-Lac | 1999 |
Evaluation of intraarticular opioid analgesia for the relief of articular pain in the domestic fowl.
Topics: Analgesia; Analgesics; Animals; Arthritis, Gouty; Buprenorphine; Chickens; Disease Models, Animal; F | 1999 |
Urolithiasis in childhood.
Topics: Adolescent; Calcium; Child; Child, Preschool; Female; Humans; Infant; Kidney Calculi; Male; Pain; Re | 2000 |
Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain.
Topics: Analgesics; Animals; Area Under Curve; Arthritis; Disease Models, Animal; Dose-Response Relationship | 2000 |
A 26-year-old man with kidney allograft failure and foot pain.
Topics: Adult; Arthritis, Gouty; Foot Diseases; Graft Rejection; Humans; Kidney Transplantation; Male; Pain; | 2001 |
[A 40-year-old man with left knee pain and tumefaction].
Topics: Acute Disease; Adult; Arthritis, Gouty; Humans; Knee Joint; Male; Pain; Synovitis; Uric Acid | 2001 |
Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain.
Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Inflammation; Lactones | 2002 |
Patchy renal vasoconstriction after exercise in a child without renal hypouricemia.
Topics: Abdomen; Acute Kidney Injury; Adolescent; Analgesics; Exercise; Female; Humans; Pain; Renal Circulat | 2002 |
Pathologic quiz case: a soft tissue mass with bone destruction. Gouty tophus.
Topics: Aged; Biopsy; Elbow Joint; Gout; Humans; Male; Pain; Radiography; Uric Acid | 2002 |
[Spinal complaints of hyperuricemic patients].
Topics: Back Pain; Female; Gout; Headache; Humans; Male; Neurologic Manifestations; Osteoarthritis; Pain; Sp | 1976 |
Acute arthralgia (gout?) after tricrynafen.
Topics: Glycolates; Gout; Humans; Hypertension; Joint Diseases; Male; Middle Aged; Pain; Ticrynafen; Uric Ac | 1979 |
Comparison of glucose, fructose and xylitol for parenteral alimentation in metabolically healthy men.
Topics: Abdomen; Fasting; Fructose; Glucose; Humans; Male; Pain; Parenteral Nutrition; Time Factors; Uric Ac | 1976 |
Factors in delayed muscle soreness.
Topics: Adult; Creatinine; Electromyography; Evoked Potentials; Female; Heart Rate; Humans; Hydroxyproline; | 1977 |
Multiple myeloma.
Topics: Aged; Bacterial Infections; Bence Jones Protein; Blood Viscosity; Bone Diseases; Humans; Hypercalcem | 1975 |
Multiple myeloma: review of 869 cases.
Topics: Adult; Aged; Bacterial Infections; Blood Cell Count; Blood Sedimentation; Bone and Bones; Calcium; C | 1975 |
[Interference of noramidopyrin and its derivatives on the dosage of uric acid].
Topics: Adult; Aminopyrine; Dipyrone; Drug Interactions; Female; Humans; Hydrogen Peroxide; In Vitro Techniq | 1975 |
[Diffuse articular chondrocalcinosis and Paget's disease].
Topics: Adult; Aged; Alkaline Phosphatase; Chondrocalcinosis; Diabetes Complications; Female; Humans; Hydrox | 1975 |
The prevalence of fibromyalgia among women aged 20-49 years in Arendal, Norway.
Topics: Adult; Blood Cell Count; Blood Chemical Analysis; Female; Fibromyalgia; Humans; Joints; Middle Aged; | 1992 |
Intraarticular noninflammatory free urate suspension (urate milk) in 3 patients with painful joints.
Topics: Aged; Alcoholism; Crystallization; Exudates and Transudates; Female; Gout; Humans; Knee Joint; Neutr | 1990 |
The epidemiology of the acute flank pain syndrome from suprofen.
Topics: Acute Kidney Injury; Adult; Asthma; Case-Control Studies; Exercise; Female; Humans; Incidence; Kidne | 1989 |
Effect of deafferentation on the levels of uric acid in the spinal cord of the rat.
Topics: Afferent Pathways; Animals; Functional Laterality; Male; Neurons, Afferent; Pain; Rats; Spinal Cord; | 1989 |
Alcohol consumption in arthritic patients: clinical and laboratory studies.
Topics: Alcohol Drinking; Arthritis, Rheumatoid; Erythrocyte Volume; Female; Femur Head Necrosis; gamma-Glut | 1985 |
Interaction between allopurinol and pyrazinamide.
Topics: Adult; Allopurinol; Drug Interactions; Drug Therapy, Combination; Humans; Joint Diseases; Male; Pain | 1988 |
Effect of the forebrain on flexion reflexes in rats with ankle joint urate arthritis.
Topics: Animals; Ankle Joint; Arthritis; Decerebrate State; Efferent Pathways; Frontal Lobe; Male; Pain; Rat | 1988 |
Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain.
Topics: Acute Disease; Adult; Humans; Kidney Concentrating Ability; Kidney Diseases; Male; Pain; Phenylpropi | 1988 |
Analgesic effects of serotonin microinjection into nucleus raphe magnus and nucleus raphe dorsalis evaluated by the monosodium urate (MSU) tonic pain model in the rat.
Topics: Analgesia; Animals; Male; Microinjections; Naloxone; Organ Specificity; Pain; Raphe Nuclei; Rats; Ra | 1987 |
[Arresting an acute attack of gout. Open pilot study in 98 patients].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation; Female; Gout; Humans; Male; | 1985 |
[Familial encephalopathy with oligophrenia and congenital indifference to pain and Laurence-Moon-Bardet-Biedl syndrome].
Topics: Alkaline Phosphatase; Brain Diseases; Child; Esterases; Female; Glucosephosphate Dehydrogenase; Huma | 1970 |
[Pain of the joint].
Topics: Blood Sedimentation; Complement System Proteins; gamma-Globulins; Humans; Joint Diseases; Methods; N | 1969 |
Diagnosis of angina pectoris at the present time.
Topics: Angina Pectoris; Cholesterol; Coronary Angiography; Coronary Circulation; Diagnosis, Differential; E | 1974 |
[Juvenile gout of the hip-joints (author's transl)].
Topics: Adolescent; Age Factors; Child; Gout; Hip; Hip Joint; Humans; Male; Pain; Radiography; Uric Acid | 1973 |
[General medical measures in neoplastic diseases and their complications].
Topics: Anemia; Central Nervous System Diseases; Humans; Hypercalcemia; Hyperinsulinism; Hyperparathyroidism | 1967 |
Chronic lead nephropathy.
Topics: Adult; Bone and Bones; Chelating Agents; Child; Child, Preschool; Edetic Acid; Environmental Exposur | 1973 |
A clinical syndrome characteristic of primary Type IV-V hyperlipoproteinaemia.
Topics: Abdomen; Adult; Cholesterol; Chylomicrons; Clofibrate; Diabetes Complications; Diet, Reducing; Elect | 1974 |
Metabolic and clinical effects of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).
Topics: Adult; Aged; Anti-Inflammatory Agents; Bilirubin; Blood Cell Count; Diuresis; Female; Hemoglobinomet | 1972 |
The medical problems of mass participation in athletic competition. The "City-to-Surf" race.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Blood Glucose; Body Temperature; Creatinine; Dehydra | 1972 |
Factors influencing the response of lesions of the rotator cuff of the shoulder to local steroid injection.
Topics: Adrenal Cortex Hormones; Adult; Aged; Blood Sedimentation; Cervical Vertebrae; Female; Humans; Injec | 1969 |
Plasma uric acid levels in children.
Topics: Abdomen; Adolescent; Child; Child, Preschool; Female; Growth; Humans; Infant; Infant, Newborn; Male; | 1969 |
Inhibitory effects of indomethacin, aspirin and certain other drugs on inflammations induced in rat and dog by carrageenan, sodium urate and ellagic acid.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Benzopyrans; Carrageenan; Cellulose; Dogs; Indomethacin; | 1970 |